2020 American Transplant Congress
Impact of Alemtuzumab Induction on Cardiac Allograft Vasculopathy in Orthotopic Heart Transplant Recipients
*Purpose: Cardiac allograft vasculopathy (CAV) is impacted by acute rejection and ultimately limits long-term survival of orthotopic heart transplant (OHT) recipients, thus there is interest…2020 American Transplant Congress
Pancreas Transplant in Patients Older Than 50: An Analysis of Outcomes and Immunosuppression
*Purpose: Pancreas transplant (PT) is the ideal therapy for many patients with diabetes and kidney failure. There are limited published data addressing the impact of…2020 American Transplant Congress
Thymoglobulin (ATG) Induction vs. Campath vs. Simulect in DCD Kidneys in UK; Induction Regimes Play a Role after All
*Purpose: Controlled DCD kidneys have increased dramatically in UK. They suffer from a higher rate of DGF and, often in UK, come from older donors…2020 American Transplant Congress
Safety Outcomes in Lower-Weight vs Higher-Weight Recipients of Fixed Dose Alemtuzumab for Kidney Transplant Induction
Ochsner Medical Center, New Orleans, LA
*Purpose: Alemtuzumab is a lymphocyte-depleting monoclonal antibody used for renal transplant induction, and is associated with significant leukopenia, increased infections and malignancy. Multiple dosing strategies…2020 American Transplant Congress
Ten Year Results of a Single Center Study of Rabbit Anti-Thymocyte Globulin Compared to Alemtuzumab Induction in Simultaneous Pancreas-Kidney Transplantation
Abdominal Transplant Surgery, Wake Forest Baptist Health, Winston Salem, NC
*Purpose: The study purpose was to analyze 10-year outcomes of depleting antibody induction agents in simultaneous pancreas-kidney transplant (SPKT) at a single center*Methods: From 2/02…2020 American Transplant Congress
Anti-Thymocyte Globulins Induced Immunomodulatory Effect and Increased Regulatory T Cell in a In Vitro Model of Allogeneic Cell Coculture
*Purpose: Two types of Anti-Thymocyte Globulins (ATG) are commonly used in renal transplantation (Thymoglobuline and Grafalon) and induce severe, dose-dependent and sometimes persistent CD4+ T…2020 American Transplant Congress
Evaluation of Infectious and Malignant Complications in Elderly Renal Transplant Recipients Receiving Alemtuzumab Compared to Basiliximab
*Purpose: The choice of induction immunosuppression can affect several outcomes after kidney transplant (KTx), especially for elderly recipients. For this population, there is limited data…2020 American Transplant Congress
Comparative Study between ATG and Grafalon as Induction Agent in Renal Transplant Recipient
Kidney and Liver Transplant, Shahid Dharmabhakta National Transplant Center, Kathmandu, Nepal
*Purpose: Renal transplantation (Rtx) remains the most effective treatment for of end-stage renal disease (ESRD). The development of induction therapy has significantly reduced the incidence…2020 American Transplant Congress
Donor-Derived Cell-Free DNA Levels During Early Rejection after Kidney Transplant May Be Impacted by Type of Induction Agent Received
*Purpose: Donor-derived cell-free DNA (dd-cfDNA) is an injury biomarker that detects rejection in kidney transplant recipients (KTR). It is reported as % cfDNA from the…2020 American Transplant Congress
Incident Malignancies among Post Kidney-Transplant Patients by Type of Induction Immunosuppression and by Age
Johns Hopkins University, Baltimore, MD
*Purpose: Adult kidney-transplant (KT) recipients have a differential risk of malignancies based on their induction immunosuppression (IS) therapy. However, older recipients are more likely to…
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- …
- 31
- Next Page »